| Ãû³Æ | Anti-Eribulin Monoclonal Antibody |
| ÀàÐÍ | Monoclonal |
| ´¿¶È | >90% as determined by SDS-PAGE |
| żÁªÇé¿ö | Non-conjugated |
| ÃâÒßËÞÖ÷ | Rabbit |
| ÑÇÐÍ | IgG |
| ´¿»¯·½·¨ | Protein G purified |
| ÑéÖ¤Ó¦ÓÃƽ̨ | ELISA |
| »º³åÒº | 10mM PBS, pH7.4 |
| ´¢´æ·½Ê½ | Please pack the antibodies into appropriate packaging (recommended per use) and store them in a -80 ¡æ freezer to avoid repeated freezing and thawing. |
| SDS-PAGE |  |
| Ó¦ÓÃ | ELISA |
| ÍƼöÓÃÁ¿ | 0.1 ?g/mL-1 ?g/mL |
| DTA0032 | |
| EC50 | 2.610 ng/mL |
Pre coated with BSA Eribulin small molecule protein (2 ¦Ìg/well) on ELISA plates, then added with continuously diluted anti Eribulin Monoclonal Antibody solution, washed, and incubated with secondary antibody for ELISA reading. Based on the above data, the EC50 for the binding of anti Eribulin Monoclonal Antibody to BSA Eribulin small molecule protein is 2.610 ng/mL.
Eribulin is a cell microtubule dynamics inhibitor and a soft sponge like anti-tumor drug. ADC loaded with Eribulin has a strong bystander effect and good clinical efficacy. Due to the release of payload after ADC administration, there is an increase in unbound payload and changes in ADC composition (i.e. DAR distribution). In order to address the challenges and difficulties in ADC drug PK analysis, a high-quality and high affinity anti Eribulin payload antibody can be used for ADC PK detection and DAR value analysis, which helps evaluate ADC efficacy, assess payload exposure at target sites, and is crucial for providing overall evaluation such as ADC stability.
ËÕ¹«Íø°²±¸32011202001300
ËÕICP±¸2021019379ºÅ-1
|